Mallinckrodt Looks To Exit Investor Suit Over Antitrust Deal
Mallinckrodt PLC and its top executives said Tuesday that investors knew of the antitrust risk linked to its infant seizure drug Acthar and have relied on "bad math" in accusing it...To view the full article, register now.
Already a subscriber? Click here to view full article